Insider · CIK 0001970752
Marcia Belvin
Files at CTMX (CytomX Therapeutics, Inc.). First filing Mar 20, 2025, latest Mar 19, 2026.
In brief
Marcia Belvin files SEC Form 4 as officer at CTMX (CytomX Therapeutics, Inc.). Since Mar 20, 2025, Marcia Belvin has reported 0 open-market buys worth $0 and 3 open-market sells worth $251k, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Marcia Belvin has 0, so none is measured yet.
The newest scored trade: sold $202k of CTMX on Mar 17, 2026, filed Mar 19, 2026, scored 42 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $202k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTMX: CytomX Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | CytomX Therapeutics, Inc. | $202k 31,492 shares | -9% | +1162% from low-19% from high | |
| 21Weak | CytomX Therapeutics, Inc. | $37k 13,884 shares | -5% | +469% from low-18% from high | |
| 30Weak | CytomX Therapeutics, Inc. | $12k 19,512 shares | -7% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -31,492 | $6.42 | $202k | 300,760 | Mar 19, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 332,252 | Feb 4, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Feb 4, 2026 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +36,300 | $0.00 | $0 | 36,300 | Sep 30, 2025 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Performance Stock Units (PSUs)derivative | +18,150 | $0.00 | $0 | 18,150 | Sep 30, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 286,136 | Jun 17, 2025 |
| Jun 16, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -13,884 | $2.69 | $37k | 272,252 | Jun 17, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -37,500 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Mar 18, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -19,512 | $0.60 | $12k | 248,636 | Mar 20, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 205,648 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 263,148 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 6, 2025 |
Questions about Marcia Belvin
Answered from the filings on this page, as of the latest one.
Is Marcia Belvin buying or selling?
In the last 12 months Marcia Belvin reported 0 open-market buys worth $0 and 1 open-market sell worth $202k on SEC Form 4; the latest was sold $202k of CTMX on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Marcia Belvin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Marcia Belvin has 0.
Where does Marcia Belvin file Form 4?
Marcia Belvin has filed Form 4 at CTMX (CytomX Therapeutics, Inc.) as SVP, Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.